The CRISPR-SCD trial is the first clinical attempt to use a non-viral delivery approach to directly correct the sickle cell ...
Sites in Los Angeles and near San Francisco California are enrolling people with severe SCD for a trial to test a gene ...
The systemic agent is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.
"The stem cell of the fetal pancreas is present longer than scientists have seen in earlier studies with mice," Andersson Rolf says. Interestingly, the organoids grown from one of these stem cells ...
On December 4, 2024, the Food and Drug Administration granted accelerated approval to Merus (MRUS)’ zenocutuzumab-zbco for adults with the ...
The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy.
Merus (MRUS) announced that the FDA approved BIZENGRI(R) (zenocutuzumab-zbco), the first and only treatment indicated for ...
Hemagglutination would be positive for maternal cells that have been bound with ... Kleihauer-Betke acid elution tes 1 Fetal hemoglobin resists release (or elution) from its RBC under acid ...
The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.
Nov. 26, 2024 — Scientists have shed new light on how certain biological processes determine the development of neural cells. Their findings on a molecular 'bridge' complex demonstrate a new ...
A precancerous cell is a cell with certain abnormalities that makes it more likely to become cancerous. These abnormalities don't mean that it will become cancer—in fact, most don't—but the diagnosis ...